Rockwell Medical

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rockwell Medical reports record revenue and eyes global expansion

Rockwell Medical's Q4 2022 earnings call showcased strong revenue growth, operational improvements, and strategic initiatives for future profitability. While challenges in expense optimization and debt reduction persist, the company's focus on growth through international partnerships and new product developments presents promising opportunities. Overall, Rockwell Medical is on track to achieve financial stability and sustained growth in the healthcare market.

Rockwell Medical reports record revenue and progress towards profitability

Rockwell Medical (RMTI) delivered strong Q1 2023 results with record revenue and progress towards profitability. The company's strategic initiatives, including the successful transition of the Baxter business, are driving growth. Despite challenges, Rockwell Medical's focus on cost reduction and business development positions it well for future success.

Rockwell Medical reports Q2 challenges but eyes profitability in 2024

Rockwell Medical's Q2 2023 performance reflects challenges in net sales and profitability but highlights strategic progress towards financial stability and growth.
The company's strengths lie in revenue increase, expense reduction, and the acquisition of Evoqua's business, positioning it for accelerated profitability.
While facing challenges in financial results and product development, Rockwell's focus on market expansion and optimization presents opportunities for future growth and revenue diversification.

Rockwell Medical posts record Q3 sales, eyes profitability in Q4

Rockwell Medical's Q3 performance reflects strong sales growth and strategic acquisitions.
While facing margin challenges, the company's focus on profitability and leadership enhancements bode well.
Opportunities lie in market dominance, operational improvements, and leveraging customer agreements.
Maintaining financial stability and pursuing growth avenues are key priorities for Rockwell's future success.

Rockwell Medical achieves historic profitability and projects strong sales growth

Rockwell Medical's Q4 2023 performance reflects significant milestones with profitability achieved and record net sales reported. The company's strategic focus on operational efficiency, growth projections, and margin improvements indicate a positive trajectory. While challenges persist, Rockwell is well-positioned to leverage opportunities for sustained growth and profitability.

Rockwell Medical reports record Q1 sales and profitability growth

Rockwell Medical delivered robust financial results in Q1 2024, showcasing growth in net sales, gross profit, and improved profitability metrics.
The company's strategic initiatives to enhance margins, optimize operations, and reduce debt position it well for future growth and value creation.
While facing challenges in a competitive market, Rockwell's unique market position and financial discipline provide a solid foundation for sustained success.

Rockwell Medical reports record-high sales and profitability, eyes global expansion

Rockwell Medical's Q3 2024 performance reflects strong financial health, profitability, and record-high sales, underpinned by strategic initiatives and partnerships.
The company faces challenges in customer dynamics but is well-positioned to capitalize on growth opportunities in at-home dialysis and international markets.
With a focus on quality, customer service, and sustainable profitability, Rockwell Medical is poised for continued success and market expansion.
Overall, Rockwell Medical's Q3 2024 earnings call highlights resilience, adaptability, and a positive outlook for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in 1996 and is headquartered in Wixom, MI.

Rockwell Medical (RMTI) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.18 per share a year ago.

Rockwell Medical (RMTI) Tops Q2 Earnings and Revenue Estimates

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical today announced financial and operational results for the three and six months ended June 30, 2024.

Rockwell Medical Reports Profitability on a Cash Flow and Adjusted EBITDA Basis in the Second Quarter of 2024

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical's Convenience Pack offers a number of advantages for home hemodialysis patients and acute care dialysis facilities.

Rockwell Medical Launches Convenience Pack to Support Home Hemodialysis and Acute Dialysis Facilities

Rockwell is a microcap manufacturer of hemodialysis concentrates for kidney failure patients, trading at under 1x full-year 2023 revenue. The company has a significant market opportunity with the growing number of kidney failure patients and potential for expansion into the home dialysis market. Despite a discounted valuation, Rockwell's growth trajectory, focus on profitability, and management execution make it a compelling investment with substantial upside potential.

Rockwell Medical Looks Like A Speculative Buy As It Approaches Profitability

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical's president and CEO, Dr. Mark Strobeck, to present at the H.C. Wainwright 3rd Annual Kidney Conference.

Rockwell Medical to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its financial and operational results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024.

Rockwell Medical to Release Second Quarter 2024 Results on Thursday, August 8, 2024

BioAtla, Inc

Immuneering Corp

With the third quarter in full swing, the bulls have not lost their grip on equities.

3 Penny Stocks With 735% Average Upside, According to Wall Street

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Mr. Chole has played a key role in helping Rockwell Medical increase its market share and broaden its product portfolio.

Rockwell Medical Promotes Tim Chole to Chief Commercial Officer

Rockwell Medical, Inc. (NASDAQ:RMTI ) Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Heather Hunter - Senior Vice President, Chief Corporate Affairs Officer Mark Strobeck - President & Chief Executive Officer Jesse Neri - Senior Vice President, Finance Conference Call Participants Ram Selvaraju - H.C. Wainwright Anthony Vendetti - Maxim Group Operator Good morning, and welcome to Rockwell Medical's First Quarter 2024 Results Conference Call and Webcast.

Rockwell Medical, Inc. (RMTI) Q1 2024 Earnings Call Transcript

Rockwell Medical (RMTI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.10 per share a year ago.

Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical (Nasdaq: RMTI) today announced financial and operational results for the three months ended March 31, 2024.

Rockwell Medical Announces First Quarter 2024 Results, Raises 2024 Guidance

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical enters into a new direct supply agreement with one of the largest health systems in the Mountain West Region of the United States.

Rockwell Medical Continues to Expand its Distribution Capabilities in Western United States

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its financial and operational results for the first quarter ended March 31, 2024 on Tuesday, May 14, 2024.

Rockwell Medical to Release First Quarter 2024 Results on Tuesday, May 14, 2024

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical enters into new and expanded distribution agreements with BioNuclear and Atlantic Medical International, respectively.

Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda

In the latest trading session, Rockwell Medical (RMTI) closed at $1.65, marking a +1.85% move from the previous day.

Rockwell Medical (RMTI) Increases Despite Market Slip: Here's What You Need to Know

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical today announced that it has been certified as a Great Place to Work® for the second year in a row.

Rockwell Medical Named 'Great Place to Work' for Second Year in a Row

Rockwell Medical, Inc. (RMTI) Q4 2023 Earnings Call Transcript

Rockwell Medical (RMTI) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to loss of $0.20 per share a year ago.

Rockwell Medical (RMTI) Q4 Earnings and Revenues Beat Estimates

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months and twelve months ended December 31, 2023. "2023 was a transformative year for Rockwell Medical, making it the second year in a row that we have provided guidance and met or exceeded that gu.

Rockwell Medical Achieves Profitability on an Adjusted EBITDA Basis in the Fourth Quarter 2023 and Record Net Sales, Gross Profit and Gross Margin for the Full-Year 2023

Rockwell Medical (RMTI) concluded the recent trading session at $1.54, signifying a +1.32% move from its prior day's close.

Rockwell Medical (RMTI) Rises As Market Takes a Dip: Key Facts

In the closing of the recent trading day, Rockwell Medical (RMTI) stood at $1.48, denoting a +0.68% change from the preceding trading day.

Rockwell Medical (RMTI) Ascends While Market Falls: Some Facts to Note

In the closing of the recent trading day, Rockwell Medical (RMTI) stood at $1.37, denoting no change from the preceding trading day.

Rockwell Medical (RMTI) Flat As Market Gains: What You Should Know

In the closing of the recent trading day, Rockwell Medical (RMTI) stood at $1.34, denoting a -0.74% change from the preceding trading day.

Why Rockwell Medical (RMTI) Dipped More Than Broader Market Today

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the fourth quarter and full-year ended December 31, 2023 on Thursday, March 21, 2024.

Rockwell Medical to Release Fourth Quarter and Full-Year 2023 Results on Thursday, March 21, 2024

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Defers principal payments of $8M up to 3yrs, reduces Rockwell Medical's need for additional operating capital, and enhances the Company's cash balance.

News for Rockwell Medical Stock (RMTI)